InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,973.10
(
0.74%
)
US TECH 100
20,544.40
(
1.59%
)
Dow Jones
43,729.34
(
0.00%
)
Brent Oil
75.00
(
-0.62%
)
Bitcoin
75,787.32
(
-0.15%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120687
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Wednesday, 08/15/2007 3:04:54 AM

Wednesday, August 15, 2007 3:04:54 AM

Post# of 19309
Another player in hemophilia FoB’s: CRXL thinks its
Factor V Leiden/Cambridge compound in preclinical
development will be usable where NovoSeven is
currently used in hemophilia A with inhibitors.
According to CRXL’s 2Q07 CC, the FV L/C compound
will have a much longer half-life than NovoSeven and
will thereby be more practical for chronic prophylactic
use. A big question, of course, is what the production
cost will be.

Here is a product description from CRXL’s website:

http://www.crucell.com/R_and_D-Discovery_Programs-Protein_Discovery-Protein_Factor_V_-_Leiden/Cambri...

>>
Crucell is investigating Protein Factor V–Leiden/Cambridge expressed on our PER.C6® cell line for use as a therapeutic agent against certain bleeding disorders.

...The objective of Crucell’s factor V project is to develop a factor V molecule that can be used to compensate impaired clotting in hemophilia A patients, particularly those having inhibitors.

…The most common bleeding disorder is Hemophilia A, which is an X chromosome-linked genetic disease affecting 1 in 5,000-10,000 males worldwide. Hemophilia A is caused by a deficiency of the blood protein factor VIII, which acts as a co-factor in the clotting system. The clinical picture of hemophilia ranges from a mild to severe bleeding tendency. Males with mild hemophilia may not bleed until after serious injury, trauma, or surgery; people with moderate hemophilia may bleed after injuries and sometimes spontaneously, whereas persons with severe hemophilia A, who are 60% of all hemophilia A cases, may suffer from frequent spontaneous bleeding episodes, often affecting joints or muscles. The severity of the bleeding tendency in hemophilia A correlates well with circulating levels of factor VIII, which are 6% to 40% in mild, 1 to 6% in moderate and less than 1% of normal in severe hemophilia.

Hemophilia A is treated with the prophylactic or therapeutic administration of factor VIII purified from human plasma or obtained as recombinant protein. In particular severe hemophiliacs are at risk to develop neutralizing antibodies, so-called inhibitors, upon administration of factor VIII, which reduces or even completely abolishes the efficacy of the therapy. In severe hemophilia A, inhibitors may develop in up to 30% of the cases. Currently, patients with inhibitors will be subjected to a costly immune tolerance therapy to induce tolerance to exogenous factor VIII, which fails in 20-40% of the cases. Bleeding episodes in patients with persistent inhibitors can be treated with recombinant factor VIIa or any other factor VIII-bypassing agent, but these agents are not suitable for prevention of these episodes. Therefore, there is a medical need for prophylactic treatment in patients with factor VIII-inhibitors, which may be fulfilled with factor V-Leiden/Cambridge.

Factor V-Leiden/Cambridge contains two mutations FV-R306T/R506Q (Leiden/Cambridge), leading to APC resistance, thereby extending the half-life of the activated molecule. It is a pro-coagulant by enhancing thrombin formation. In addition to hemophilia with inhibitors, other indications for factor V-Leiden/Cambridge may include hemophilia without inhibitors, Factor V and Factor V/VIII deficiency, and bleeding disorders not due to deficiency of a clotting factor such as hemorrhagic stroke.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up